Vertex, Bristol to conduct midstage trials of hep C combo therapy

04/8/2013 | Genetic Engineering & Biotechnology News

Vertex Pharmaceuticals and Bristol-Myers Squibb signed a non-exclusive deal to initiate two midstage trials of a once-a-day combination therapy for hepatitis C. The trials will test the safety, tolerability, pharmacokinetics and viral cure rates of Vertex's VX-135, a nucleotide analogue hepatitis C virus polymerase inhibitor, in combination with Bristol's daclatasvir, an experimental NS5A replication complex inhibitor.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL